AU 007
Alternative Names: AU-007; BD-8; BDG8Latest Information Update: 11 Jul 2024
At a glance
- Originator Biolojic Design
- Developer Aulos Bioscience; Biolojic Design
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin-2 receptor alpha subunit antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 24 May 2024 Updated pharmacokinetic, adverse events and efficacy data from a phase I/II trial in Solid tumours released by Aulos Bioscience
- 16 May 2024 Aulos Bioscience enters into clinical trial and supply agreement with Ares Trading for use of Bavencio® (avelumab) in a clinical study of its lead human monoclonal antibody candidate, AU 007